{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-10T19:53:47.603811+00:00","company":{"ticker":"TVTX","cik":1438533,"company_name":"Travere Therapeutics, Inc."},"pagination":{"limit":100,"returned":42,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Everest Medicines Pte. Ltd.","detail":"license","count":1,"first_seen":"2026-06-02T11:05:07+00:00","last_seen":"2026-06-02T11:05:07+00:00","evidence_fact_ids":[51462]},{"display_name":"J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC","detail":"underwriting","count":1,"first_seen":"2026-05-11T21:10:04+00:00","last_seen":"2026-05-11T21:10:04+00:00","evidence_fact_ids":[108334]},{"display_name":"Mirum Pharmaceuticals, Inc.","detail":"asset_purchase","count":1,"first_seen":"2023-07-17T23:59:59+00:00","last_seen":"2023-07-17T23:59:59+00:00","evidence_fact_ids":[131064]}],"lender":[{"display_name":"U.S. Bank Trust Company, National Association","detail":"convertible_notes","count":1,"first_seen":"2026-05-11T21:10:04+00:00","last_seen":"2026-05-11T21:10:04+00:00","evidence_fact_ids":[55291]}],"ma_counterparty":[{"display_name":"Mirum Pharmaceuticals, Inc.","detail":"disposition","count":1,"first_seen":"2023-09-05T23:59:59+00:00","last_seen":"2023-09-05T23:59:59+00:00","evidence_fact_ids":[115235]}]},"facts":[{"fact_type":"executive_change","fact_key":"8ed9086126","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-06-16T20:34:58+00:00","payload":{"action":"named","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2026-07-01","interim":false,"role":"Executive Vice President, Head of Research & Development and Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jula Inrig was named as Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics, Inc..","evidence_excerpt":"Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001438533-26-000048","anchor_url":"https://secwatch.observer/filing/0001438533-26-000048#claim-8ed9086126","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm"},{"fact_type":"executive_change","fact_key":"c77637f705","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-06-16T20:34:58+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2027-02-17","interim":false,"role":"Chief Research Officer","role_category":"other_named_officer","successor_name":"Jula Inrig","successor_named":true},"claim":"William Rote departed as Chief Research Officer at Travere Therapeutics, Inc..","evidence_excerpt":"On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001438533-26-000048","anchor_url":"https://secwatch.observer/filing/0001438533-26-000048#claim-c77637f705","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm"},{"fact_type":"material_agreement","fact_key":"ecdfbac9c8e9c51a3587fb05d5ca9d2031e7275b","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-06-02T11:05:07+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"license","counterparty":"Everest Medicines (Singapore) Pte. Ltd.","effective_date":"2026-06-01","item_codes_triggered":["1.01"],"value_text":"upfront payment of $112.5 million"},"claim":"Travere Therapeutics, Inc. entered into Agreement with Everest Medicines (Singapore) Pte. Ltd. valued at upfront payment of $112.5 million (effective 2026-06-01).","evidence_excerpt":"On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-252474","anchor_url":"https://secwatch.observer/filing/0001193125-26-252474#claim-ecdfbac9c8e9c51a3587fb05d5ca9d2031e7275b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm"},{"fact_type":"shareholder_vote","fact_key":"daef445cb94ab32ef6b72837cd6bc82422a74d83","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-21T20:07:19+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-19","outcome":"passed","proposal_text":"Ratification of the Selection of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"279,509","votes_against":"120,699","votes_for":"80,708,265","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-05-19 meeting.","evidence_excerpt":"Proposal 5: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For 80,708,265 Votes Against 120,699 Abstentions 279,509 Broker Non-Votes —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-26-000046","anchor_url":"https://secwatch.observer/filing/0001438533-26-000046#claim-daef445cb94ab32ef6b72837cd6bc82422a74d83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm"},{"fact_type":"shareholder_vote","fact_key":"aba4623f804c86741383ae37f956657123faafe6","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-21T20:07:19+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-19","outcome":"passed","proposal_text":"Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"5,290,327","subject":null,"votes_abstain":"42,836","votes_against":null,"votes_for":"75,003,558","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-05-19 meeting.","evidence_excerpt":"Proposal 4: Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers The Company’s stockholders indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: One Year 75,003,558 Two Years 4,996 Three Years 766,756 Abstentions 42,836 Broker Non-Votes 5,290,327","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-26-000046","anchor_url":"https://secwatch.observer/filing/0001438533-26-000046#claim-aba4623f804c86741383ae37f956657123faafe6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm"},{"fact_type":"shareholder_vote","fact_key":"77affcaa5ae3c859b3271f93d53566672a39668d","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-21T20:07:19+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-19","outcome":"passed","proposal_text":"Approval, on an advisory basis, of the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"5,290,327","subject":null,"votes_abstain":"33,152","votes_against":"2,073,324","votes_for":"73,711,670","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers at the 2026-05-19 meeting.","evidence_excerpt":"Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results are as follows: Votes For 73,711,670 Votes Against 2,073,324 Abstentions 33,152 Broker Non-Votes 5,290,327","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-26-000046","anchor_url":"https://secwatch.observer/filing/0001438533-26-000046#claim-77affcaa5ae3c859b3271f93d53566672a39668d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2c174dadd808eaf13fd3b3b6261355b832215e01","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-21T20:07:19+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-19","outcome":"passed","proposal_text":"Approval of the Company's 2018 Equity Incentive Plan, as amended","proposal_type":"equity_plan","results":[{"broker_non_votes":"5,290,327","subject":null,"votes_abstain":"32,347","votes_against":"2,787,402","votes_for":"72,998,395","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Approval of the Company's 2018 Equity Incentive Plan, as amended at the 2026-05-19 meeting.","evidence_excerpt":"Proposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000. The final voting results are as follows: Votes For 72,998,395 Votes Against 2,787,402 Abstentions 32,347 Broker Non-Votes 5,290,327","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-26-000046","anchor_url":"https://secwatch.observer/filing/0001438533-26-000046#claim-2c174dadd808eaf13fd3b3b6261355b832215e01","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a75f4855fb18a02ac6b1ab0c8edb67943596a7d4","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-21T20:07:19+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-19","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"5,290,327","subject":"Roy D. Baynes, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"66,479,999","votes_withheld":"9,338,149"},{"broker_non_votes":"5,290,327","subject":"Suzanne Bruhn, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"74,711,994","votes_withheld":"1,106,154"},{"broker_non_votes":"5,290,327","subject":"Timothy Coughlin","votes_abstain":null,"votes_against":null,"votes_for":"73,695,965","votes_withheld":"2,122,183"},{"broker_non_votes":"5,290,327","subject":"Eric Dube, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"75,095,860","votes_withheld":"722,288"},{"broker_non_votes":"5,290,327","subject":"Gary Lyons","votes_abstain":null,"votes_against":null,"votes_for":"74,208,952","votes_withheld":"1,609,196"},{"broker_non_votes":"5,290,327","subject":"Jeffrey Meckler","votes_abstain":null,"votes_against":null,"votes_for":"73,469,263","votes_withheld":"2,348,885"},{"broker_non_votes":"5,290,327","subject":"John A. Orwin","votes_abstain":null,"votes_against":null,"votes_for":"74,657,472","votes_withheld":"1,160,676"},{"broker_non_votes":"5,290,327","subject":"Sandra Poole","votes_abstain":null,"votes_against":null,"votes_for":"74,551,138","votes_withheld":"1,267,010"},{"broker_non_votes":"5,290,327","subject":"Ron Squarer","votes_abstain":null,"votes_against":null,"votes_for":"74,767,455","votes_withheld":"1,050,693"},{"broker_non_votes":"5,290,327","subject":"Ruth Williams-Brinkley","votes_abstain":null,"votes_against":null,"votes_for":"74,764,679","votes_withheld":"1,053,469"}]},"claim":"Travere Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-19 meeting.","evidence_excerpt":"The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2027 Annual Meeting of Stockholders. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Roy D. Baynes, M.D., Ph.D. 66,479,999 9,338,149 5,290,327 Suzanne Bruhn, Ph.D. 74,711,994 1,106,154 5,290,327 Timothy Coughlin 73,695,965 2,122,183 5,290,327 Eric Dube, Ph.D. 75,095,860 722,288 5,290,327 Gary Lyons 74,208,952 1,609,196 5,290,327 Jeffrey Meckler 73,469,263 2,348,885 5,290,327 John A. Orwin 74,657,472 1,160,676 5,290,327 Sandra Poole 74,551,138 1,267,010 5,290,327 Ron Squarer 74,767,455 1,050,693 5,290,327 Ruth Williams-Brinkley 74,764,679 1,053,469 5,290,327","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-26-000046","anchor_url":"https://secwatch.observer/filing/0001438533-26-000046#claim-a75f4855fb18a02ac6b1ab0c8edb67943596a7d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm"},{"fact_type":"material_agreement","fact_key":"bfddbcf9258e102d67f64b0e51abe0a00f648c4e","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-11T21:10:04+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters","effective_date":"2026-05-11","item_codes_triggered":["1.01"],"value_text":"$525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032"},"claim":"Travere Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (effective 2026-05-11).","evidence_excerpt":"On May 11, 2026 (the “Closing Date”), Travere Therapeutics, Inc. (the “Company”) completed its registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (such notes, the “Notes,” and such offering, the “Offering”) pursuant to the underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-217100","anchor_url":"https://secwatch.observer/filing/0001193125-26-217100#claim-bfddbcf9258e102d67f64b0e51abe0a00f648c4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/0001193125-26-217100-index.htm"},{"fact_type":"debt_financing","fact_key":"a1b8c676a0b7a31129101c6246192f7821170d78","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-11T21:10:04+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-11","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"0.50%","item_codes_triggered":["2.03"],"maturity_text":"May 15, 2032","principal_text":"$525.0 million aggregate principal amount"},"claim":"Travere Therapeutics, Inc. incurred convertible notes of $525.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.50% maturing May 15, 2032.","evidence_excerpt":"completed its registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-217100","anchor_url":"https://secwatch.observer/filing/0001193125-26-217100#claim-a1b8c676a0b7a31129101c6246192f7821170d78","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/0001193125-26-217100-index.htm"},{"fact_type":"earnings_release","fact_key":"ec7f9dcceb2aefd312e3fdf4f06e5017b18f05d6","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":"$0.40 per basic share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$124.5 million"},"claim":"Travere Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $124.5 million, net income Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share, EPS $0.40 per basic share.","evidence_excerpt":"supporting a compelling long-term trajectory for the Company.” Financial Results for the Quarter Ended March 31, 2026 U.S. net product sales for the first quarter of 2026 were $124.5 million, compared to $75.9 million for the same period in 2025. The increase is attributable to growth in sales of FILSPARI. Research and development (R&D) expenses for the first quarter","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-26-000041","anchor_url":"https://secwatch.observer/filing/0001438533-26-000041#claim-ec7f9dcceb2aefd312e3fdf4f06e5017b18f05d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/0001438533-26-000041-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7625da6e7f184b920f1d3dd636a0350bf5b4e376","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Ratification of the Selection of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","votes_abstain_text":"52,434","votes_against_text":"2,184,775","votes_for_text":"60,467,774"},"claim":"Travere Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-24-000022","anchor_url":"https://secwatch.observer/filing/0001438533-24-000022#claim-7625da6e7f184b920f1d3dd636a0350bf5b4e376","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e5fee682e474d8d79902c0fecbeb59ee75eabf2b","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Approval, on an advisory basis, of the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","votes_abstain_text":"42,079","votes_against_text":"2,854,506","votes_for_text":"55,789,526"},"claim":"Travere Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-24-000022","anchor_url":"https://secwatch.observer/filing/0001438533-24-000022#claim-e5fee682e474d8d79902c0fecbeb59ee75eabf2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1c5dcd636b2bcc75552434e749aaa6ef273d5e4a","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Approval of the Company’s 2018 Equity Incentive Plan, as amended","proposal_type":"equity_plan","votes_abstain_text":"212,086","votes_against_text":"22,098,658","votes_for_text":"36,375,367"},"claim":"Travere Therapeutics, Inc. shareholders approved Approval of the Company’s 2018 Equity Incentive Plan, as amended at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-24-000022","anchor_url":"https://secwatch.observer/filing/0001438533-24-000022#claim-1c5dcd636b2bcc75552434e749aaa6ef273d5e4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5a16cd2e67e356e17d825b1c50de92c6a171764f","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","votes_abstain_text":null,"votes_against_text":null,"votes_for_text":null},"claim":"Travere Therapeutics, Inc. shareholders approved Election of Directors at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2025 Annual Meeting of Stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-24-000022","anchor_url":"https://secwatch.observer/filing/0001438533-24-000022#claim-5a16cd2e67e356e17d825b1c50de92c6a171764f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm"},{"fact_type":"earnings_release","fact_key":"bfdc2ca28e96e76c06b572ac59abbe647d0aec14","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":"$1.76 per basic share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$136.1 million, or $1.76 per basic share","period_text":"the first quarter of 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$40.0 million"},"claim":"Travere Therapeutics, Inc. reported the first quarter of 2024 results: revenue $40.0 million, net income $136.1 million, or $1.76 per basic share, EPS $1.76 per basic share.","evidence_excerpt":"Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-24-000019","anchor_url":"https://secwatch.observer/filing/0001438533-24-000019#claim-bfdc2ca28e96e76c06b572ac59abbe647d0aec14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/0001438533-24-000019-index.htm"},{"fact_type":"earnings_release","fact_key":"e60e5563ce6261b1c231ad9ea83cac02f70e5ba6","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and fiscal year ended December 31, 2023","report_date":"2024-02-15","result_type":"reported_results","revenue_text":null},"claim":"Travere Therapeutics, Inc. reported financial results for the quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On February 15, 2024, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-24-000003","anchor_url":"https://secwatch.observer/filing/0001438533-24-000003#claim-e60e5563ce6261b1c231ad9ea83cac02f70e5ba6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/0001438533-24-000003-index.htm"},{"fact_type":"earnings_release","fact_key":"bdc760a56639fd5704990929245c3fcbbbf77219","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year 2023","report_date":"2024-01-08","result_type":"preliminary_results","revenue_text":"approximately $128 million"},"claim":"Travere Therapeutics, Inc. reported fiscal year 2023 results: revenue approximately $128 million.","evidence_excerpt":"For the fiscal year 2023, the Company expects net product sales from continuing operations to be approximately $128 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-003866","anchor_url":"https://secwatch.observer/filing/0001193125-24-003866#claim-bdc760a56639fd5704990929245c3fcbbbf77219","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm"},{"fact_type":"earnings_release","fact_key":"ddf5890e9cfb31c016d19a410a1fb46587e13ff5","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter of 2023","report_date":"2024-01-08","result_type":"preliminary_results","revenue_text":"$15 million"},"claim":"Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.","evidence_excerpt":"the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-003866","anchor_url":"https://secwatch.observer/filing/0001193125-24-003866#claim-ddf5890e9cfb31c016d19a410a1fb46587e13ff5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm"},{"fact_type":"restructuring_charge","fact_key":"0de3cd10ec39bf23b9931196b7c310f124fed98f","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-12-04T23:59:59+00:00","payload":{"affected_area":"non-field-based employees","charge_text":"approximately $12-14 million","effective_date":"2023-11-30","event_type":"restructuring","headcount_text":"approximate 20% workforce reduction","item_codes_triggered":["2.05"]},"claim":"Travere Therapeutics, Inc. announced a restructuring with charges of approximately $12-14 million affecting non-field-based employees (approximate 20% workforce reduction).","evidence_excerpt":"the Company approved a strategic reorganization (the “Strategic Reorganization”). The Strategic Reorganization was approved by the Company on November 30, 2023 and is expected to be completed by the second quarter of 2024. As part of the Strategic Reorganization, the Company is implementing an approximate 20% workforce reduction focused on non-field-based employees. The Company estimates that it will incur aggregate non-recurring charges of approximately $12-14 million in connection with the Strategic Reorganization","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000050","anchor_url":"https://secwatch.observer/filing/0001438533-23-000050#claim-0de3cd10ec39bf23b9931196b7c310f124fed98f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000050/0001438533-23-000050-index.htm"},{"fact_type":"earnings_release","fact_key":"1010ebc21444619588b339c3d04c4aef96c8cd94","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":null},"claim":"Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000046","anchor_url":"https://secwatch.observer/filing/0001438533-23-000046#claim-1010ebc21444619588b339c3d04c4aef96c8cd94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/0001438533-23-000046-index.htm"},{"fact_type":"ma_transaction","fact_key":"ec65f4aad82f3f59e82bc01ed38d855dc8f79cdc","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-09-05T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2023-08-31","consideration_text":"$210,000,000","counterparty":"Mirum Pharmaceuticals, Inc.","effective_date":"2023-08-31","item_codes_triggered":["2.01"]},"claim":"Travere Therapeutics, Inc. completed a disposition involving Mirum Pharmaceuticals, Inc. for $210,000,000 (closed 2023-08-31).","evidence_excerpt":"of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”). In connection with the Closing, Mirum paid the Company an upfront cash payment of $210,000,000. Pursuant to the Purchase Agreement, after the Closing, the Company is eligible to receive up to $235,000,000 upon the achievement of certain milestones based on specified","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-228130","anchor_url":"https://secwatch.observer/filing/0001193125-23-228130#claim-ec65f4aad82f3f59e82bc01ed38d855dc8f79cdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/0001193125-23-228130-index.htm"},{"fact_type":"earnings_release","fact_key":"fe105de4b06fa0f26c77529900582569f08707a3","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","payload":{"eps_text":"$1.13 per basic share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.13 per basic share","period_text":"the second quarter of 2023","report_date":"2023-08-03","result_type":"reported_results","revenue_text":"$59.7 million"},"claim":"Travere Therapeutics, Inc. reported the second quarter of 2023 results: revenue $59.7 million, net income $1.13 per basic share, EPS $1.13 per basic share.","evidence_excerpt":"treatment standards from pipeline and strengthens financial foundation; transaction expected to close in third quarter of 2023 • Total revenue for the second quarter of 2023 was $59.7 million, consisting of $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of June 30,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000036","anchor_url":"https://secwatch.observer/filing/0001438533-23-000036#claim-fe105de4b06fa0f26c77529900582569f08707a3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/0001438533-23-000036-index.htm"},{"fact_type":"material_agreement","fact_key":"be321d02bdbae65bdd963593d22fe7e66905a3a7","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-07-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Mirum Pharmaceuticals, Inc.","effective_date":"2023-07-16","item_codes_triggered":["1.01"],"value_text":"up to $445,000,000 in cash"},"claim":"Travere Therapeutics, Inc. entered into Asset Purchase Agreement with Mirum Pharmaceuticals, Inc. valued at up to $445,000,000 in cash (effective 2023-07-16).","evidence_excerpt":"On July 16, 2023, Travere Therapeutics, Inc. (the “Company”) executed an Asset Purchase Agreement (the “Purchase Agreement”) with Mirum Pharmaceuticals, Inc., a Delaware corporation (“Mirum”). Subject to the terms and conditions of the Purchase Agreement, at the closing (the “Closing”) of the transactions contemplated by the Purchase Agreement (the “Asset Purchase”), Mirum will purchase from the Company substantially all of the assets that are primarily related to the Company’s business of development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”) for an aggregate purchase price, subject to certain adjustments pursuant to the terms of the Purchase Agreement, of up to $445,000,000 in cash, with $210,000,000 due at Closing and up to $235,000,000 after the Closing, upon the achievement of certain milestones based on specified amounts of annual net sales","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-187704","anchor_url":"https://secwatch.observer/filing/0001193125-23-187704#claim-be321d02bdbae65bdd963593d22fe7e66905a3a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523187704/0001193125-23-187704-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8f2f58c1242d94a2392b99aa1d6ee191f90e8af4","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"31,056","votes_against":"30,013","votes_for":"63,811,465","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000027","anchor_url":"https://secwatch.observer/filing/0001438533-23-000027#claim-8f2f58c1242d94a2392b99aa1d6ee191f90e8af4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c4a04cf7526aadf3147761d9822ff34c10d8751c","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Advisory approval of the compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,230,318","subject":null,"votes_abstain":"26,929","votes_against":"5,363,550","votes_for":"56,251,737","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Advisory approval of the compensation of named executive officers at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000027","anchor_url":"https://secwatch.observer/filing/0001438533-23-000027#claim-c4a04cf7526aadf3147761d9822ff34c10d8751c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b4b2039844cadd1d4c6b14847c703341af4b395e","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Approval of the Company's 2018 Equity Incentive Plan, as amended","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,230,319","subject":null,"votes_abstain":"25,493","votes_against":"6,275,725","votes_for":"55,340,997","votes_withheld":null}]},"claim":"Travere Therapeutics, Inc. shareholders approved Approval of the Company's 2018 Equity Incentive Plan, as amended at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000027","anchor_url":"https://secwatch.observer/filing/0001438533-23-000027#claim-b4b2039844cadd1d4c6b14847c703341af4b395e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b142d3916b16bf1b23ec54452fccfc859ebca68d","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Election of ten directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,230,318","subject":"Roy D. Baynes, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"58,297,968","votes_withheld":"3,344,248"},{"broker_non_votes":"2,230,318","subject":"Suzanne Bruhn, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"58,517,914","votes_withheld":"3,124,302"},{"broker_non_votes":"2,230,318","subject":"Timothy Coughlin","votes_abstain":null,"votes_against":null,"votes_for":"58,558,298","votes_withheld":"3,083,918"},{"broker_non_votes":"2,230,318","subject":"Eric Dube, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"58,647,084","votes_withheld":"2,995,132"},{"broker_non_votes":"2,230,318","subject":"Gary Lyons","votes_abstain":null,"votes_against":null,"votes_for":"57,605,286","votes_withheld":"4,036,930"},{"broker_non_votes":"2,230,318","subject":"Jeffrey Meckler","votes_abstain":null,"votes_against":null,"votes_for":"58,125,179","votes_withheld":"3,517,037"},{"broker_non_votes":"2,230,318","subject":"John A. Orwin","votes_abstain":null,"votes_against":null,"votes_for":"50,649,777","votes_withheld":"10,992,439"},{"broker_non_votes":"2,230,318","subject":"Sandra Poole","votes_abstain":null,"votes_against":null,"votes_for":"58,355,010","votes_withheld":"3,287,206"},{"broker_non_votes":"2,230,318","subject":"Ron Squarer","votes_abstain":null,"votes_against":null,"votes_for":"58,579,598","votes_withheld":"3,062,618"},{"broker_non_votes":"2,230,318","subject":"Ruth Williams-Brinkley","votes_abstain":null,"votes_against":null,"votes_for":"56,615,941","votes_withheld":"5,026,275"}]},"claim":"Travere Therapeutics, Inc. shareholders approved Election of ten directors at the 2023-05-17 meeting.","evidence_excerpt":"Proposal 1: Election of Directors The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2023 Annual Meeting of Stockholders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000027","anchor_url":"https://secwatch.observer/filing/0001438533-23-000027#claim-b142d3916b16bf1b23ec54452fccfc859ebca68d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm"},{"fact_type":"earnings_release","fact_key":"d050285abbf8b76dc2c10294bd80558d56cfc46a","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":"$1.27 per basic share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$86.3 million","period_text":"the quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":"$57.0 million"},"claim":"Travere Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $57.0 million, net income $86.3 million, EPS $1.27 per basic share.","evidence_excerpt":"IgAN in Europe expected in second half 2023 • Net product sales of FILSPARI totaled $3.0 million for the first quarter of 2023 • Total revenue for the first quarter of 2023 was $57.0 million, consisting of $50.3 million in net product sales and $6.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of March 31,","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-23-000023","anchor_url":"https://secwatch.observer/filing/0001438533-23-000023#claim-d050285abbf8b76dc2c10294bd80558d56cfc46a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/0001438533-23-000023-index.htm"},{"fact_type":"auditor_change","fact_key":"35dea603b04563fd81e0b601b01ef7b5da647fbb","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Ernst & Young LLP","disagreement_text":null,"effective_date":"2023-04-06","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Travere Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"the Audit Committee approved the appointment of EY as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000012","anchor_url":"https://secwatch.observer/filing/0001438533-23-000012#claim-35dea603b04563fd81e0b601b01ef7b5da647fbb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/0001438533-23-000012-index.htm"},{"fact_type":"auditor_change","fact_key":"82fca8ac06b922d167829617fee42dfcbea7c6e4","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"BDO USA, LLP","disagreement_text":null,"effective_date":"2023-04-06","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Travere Therapeutics, Inc. dismissed BDO USA, LLP as its auditor.","evidence_excerpt":"On April 6, 2023, the Audit Committee dismissed BDO as the Company’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000012","anchor_url":"https://secwatch.observer/filing/0001438533-23-000012#claim-82fca8ac06b922d167829617fee42dfcbea7c6e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/0001438533-23-000012-index.htm"},{"fact_type":"earnings_release","fact_key":"7fdb642f973201775ed25bf79a5ad16c0e6a1a87","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($65.8 million, or $1.03 per basic share)","period_text":"fourth quarter and full year ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$55.9 million"},"claim":"Travere Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $55.9 million, net income ($65.8 million, or $1.03 per basic share).","evidence_excerpt":"confirmatory endpoints in the ongoing Phase 3 PROTECT Study of sparsentan in IgAN expected in the fourth quarter of 2023 • Total revenue for the fourth quarter of 2022 was $55.9 million, consisting of $52.3 million in net product sales and $3.5 million in licensing and collaboration revenue • Total revenue for the full year 2022 was $212.0 million, consisting of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001438533-23-000006","anchor_url":"https://secwatch.observer/filing/0001438533-23-000006#claim-7fdb642f973201775ed25bf79a5ad16c0e6a1a87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/0001438533-23-000006-index.htm"},{"fact_type":"earnings_release","fact_key":"68cc026305d23aa49be73c4694154e2792b2ce27","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2022","report_date":"2023-01-09","result_type":"preliminary_results","revenue_text":"$212 million"},"claim":"Travere Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $212 million.","evidence_excerpt":"For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-004120","anchor_url":"https://secwatch.observer/filing/0001193125-23-004120#claim-68cc026305d23aa49be73c4694154e2792b2ce27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm"},{"fact_type":"earnings_release","fact_key":"51e5d868e7015ca6e89d93ea8e708ba510bf5b69","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-01-09","result_type":"preliminary_results","revenue_text":"approximately $52 million"},"claim":"Travere Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue approximately $52 million.","evidence_excerpt":"the Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-004120","anchor_url":"https://secwatch.observer/filing/0001193125-23-004120#claim-51e5d868e7015ca6e89d93ea8e708ba510bf5b69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm"},{"fact_type":"earnings_release","fact_key":"e7ed7e5bb74d04da5fe97bcf1640b500322db9a9","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2022-10-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended September 30, 2022","report_date":"2022-10-27","result_type":"reported_results","revenue_text":null},"claim":"Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On October 27, 2022, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2022.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001438533-22-000049","anchor_url":"https://secwatch.observer/filing/0001438533-22-000049#claim-e7ed7e5bb74d04da5fe97bcf1640b500322db9a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/0001438533-22-000049-index.htm"},{"fact_type":"executive_change","fact_key":"b88fe2f8ef","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2022-08-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christopher Cline was appointed as Chief Financial Officer at Travere Therapeutics, Inc..","evidence_excerpt":"Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of September 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-22-000036","anchor_url":"https://secwatch.observer/filing/0001438533-22-000036#claim-b88fe2f8ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/0001438533-22-000036-index.htm"},{"fact_type":"executive_change","fact_key":"411875d2fa","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2022-08-17T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"retirement","effective_date":"2022-08-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Christopher Cline","successor_named":true},"claim":"Laura Clague departed as Chief Financial Officer at Travere Therapeutics, Inc..","evidence_excerpt":"On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-22-000036","anchor_url":"https://secwatch.observer/filing/0001438533-22-000036#claim-411875d2fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/0001438533-22-000036-index.htm"},{"fact_type":"executive_change","fact_key":"83d7ab3997","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2022-04-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christopher Cline was appointed as Chief Financial Officer at Travere Therapeutics, Inc..","evidence_excerpt":"Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of the Officer Resignation Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-22-000017","anchor_url":"https://secwatch.observer/filing/0001438533-22-000017#claim-83d7ab3997","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/0001438533-22-000017-index.htm"},{"fact_type":"executive_change","fact_key":"cebe309b97","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2022-04-20T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2022-08-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Christopher Cline","successor_named":true},"claim":"Laura Clague retired as Chief Financial Officer at Travere Therapeutics, Inc..","evidence_excerpt":"On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-22-000017","anchor_url":"https://secwatch.observer/filing/0001438533-22-000017#claim-cebe309b97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/0001438533-22-000017-index.htm"},{"fact_type":"executive_change","fact_key":"2506e4fda7","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2021-10-12T23:59:59+00:00","payload":{"action":"transitioning","action_category":"role_change","departure_tone":"routine","effective_date":"2021-12-31","interim":false,"role":"executive advisor","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Noah Rosenberg changed role as executive advisor at Travere Therapeutics, Inc..","evidence_excerpt":"On October 12, 2021, Travere Therapeutics, Inc. (the “Company”) announced that its chief medical officer, Noah Rosenberg, M.D., will be transitioning to an executive advisor role at the end of 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-21-000047","anchor_url":"https://secwatch.observer/filing/0001438533-21-000047#claim-2506e4fda7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/0001438533-21-000047-index.htm"},{"fact_type":"executive_change","fact_key":"70b2734ab2","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2021-09-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-09-15","interim":false,"role":"Vice President, Corporate Controller and Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sandra Calvin was appointed as Vice President, Corporate Controller and Chief Accounting Officer at Travere Therapeutics, Inc..","evidence_excerpt":"On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved the appointment of Sandra Calvin as the Company’s principal accounting officer, effective September 15, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-21-000045","anchor_url":"https://secwatch.observer/filing/0001438533-21-000045#claim-70b2734ab2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000045/0001438533-21-000045-index.htm"},{"fact_type":"executive_change","fact_key":"52b4949ce4","cik":1438533,"ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2021-09-14T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-09-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ruth Williams-Brinkley was elected as Director at Travere Therapeutics, Inc..","evidence_excerpt":"On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved an increase in the size of the Board of Directors from 10 to 11 members and elected Ruth Williams-Brinkley to serve as a director of the Company, effective September 14, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001438533-21-000041","anchor_url":"https://secwatch.observer/filing/0001438533-21-000041#claim-52b4949ce4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000041/0001438533-21-000041-index.htm"}]}